Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cinrebafusp alfa + Tucatinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cinrebafusp alfa | PRS-343|PRS 343|PRS343 | HER2 (ERBB2) Antibody 77 TNFRSF9 Antibody 32 | Cinrebafusp alfa is a bispecific antibody that targets both TNFRSF9 (CD137; 4-1BB) and ERBB2 (HER2), potentially resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (PMID: 31138587, PMID: 39235868). | |
Tucatinib | Tukysa | ONT-380|ARRY-380|irbinitinib | HER2 Inhibitor 43 | Tukysa (tucatinib) selectivity inhibits ERBB2 (HER2), resulting in decreased proliferation and increased apoptosis in ERBB2 (HER2) expressing tumor cells (PMID: 28053022). Tukysa (tucatinib) in combination with Herceptin (trastuzumab) and Xeloda (capecitabine) is FDA approved for use in patients with advanced unresectable or metastatic ERBB2 (HER2)-positive breast cancer, including patients with brain metastasis, who have received prior anti-HER2 therapies, and in combination with Herceptin (trastuzumab) for patients with RAS wild-type ERBB2 (HER2)-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05190445 | Phase II | Cinrebafusp alfa + Tucatinib Cinrebafusp alfa + Paclitaxel + Ramucirumab | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | Active, not recruiting | USA | 1 |